IL156364A0 - Prodrugs of excitatory amino acids - Google Patents
Prodrugs of excitatory amino acidsInfo
- Publication number
- IL156364A0 IL156364A0 IL15636401A IL15636401A IL156364A0 IL 156364 A0 IL156364 A0 IL 156364A0 IL 15636401 A IL15636401 A IL 15636401A IL 15636401 A IL15636401 A IL 15636401A IL 156364 A0 IL156364 A0 IL 156364A0
- Authority
- IL
- Israel
- Prior art keywords
- prodrugs
- amino acids
- excitatory amino
- excitatory
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01500007 | 2001-01-11 | ||
EP01500206 | 2001-08-02 | ||
US32978601P | 2001-10-16 | 2001-10-16 | |
EP01500263A EP1310480A1 (fr) | 2001-11-07 | 2001-11-07 | Prodrugs d'aminoacides excitants |
PCT/US2001/045866 WO2002055481A1 (fr) | 2001-01-11 | 2001-12-21 | Promedicaments d'aminoacides excitateurs |
Publications (1)
Publication Number | Publication Date |
---|---|
IL156364A0 true IL156364A0 (en) | 2004-01-04 |
Family
ID=27440162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15636401A IL156364A0 (en) | 2001-01-11 | 2001-12-14 | Prodrugs of excitatory amino acids |
Country Status (24)
Country | Link |
---|---|
US (1) | US7256217B2 (fr) |
EP (1) | EP1368304B1 (fr) |
JP (1) | JP4064237B2 (fr) |
KR (1) | KR20030090622A (fr) |
CN (1) | CN1267407C (fr) |
AR (1) | AR036007A1 (fr) |
AT (1) | ATE356111T1 (fr) |
AU (1) | AU2002228737B2 (fr) |
BR (1) | BR0116770A (fr) |
CA (1) | CA2433667C (fr) |
CZ (1) | CZ303490B6 (fr) |
DE (1) | DE60127182T2 (fr) |
DZ (1) | DZ3461A1 (fr) |
ES (1) | ES2282315T3 (fr) |
HU (1) | HUP0400620A3 (fr) |
IL (1) | IL156364A0 (fr) |
MX (1) | MXPA03006186A (fr) |
NO (1) | NO20033166L (fr) |
NZ (1) | NZ526050A (fr) |
PE (1) | PE20020829A1 (fr) |
PL (1) | PL208413B1 (fr) |
SK (1) | SK287934B6 (fr) |
SV (1) | SV2003000836A (fr) |
WO (1) | WO2002055481A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1517915B1 (fr) | 2002-06-11 | 2009-01-21 | Eli Lilly And Company | Promedicaments d'acides amines excitateurs |
WO2010111080A2 (fr) | 2009-03-27 | 2010-09-30 | Eli Lilly And Company | Traitement optimisé de la schizophrénie |
AR079343A1 (es) * | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
US9296710B2 (en) | 2011-06-17 | 2016-03-29 | Eli Lilly And Company | Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist |
AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
US11384061B2 (en) | 2018-04-17 | 2022-07-12 | Bayer Aktiengesellschaft | Process for preparing esters of N-acylated amino acids with acid-labile keto protective group functions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
PL182285B1 (pl) | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL |
AU3364995A (en) | 1994-08-12 | 1996-03-07 | Eli Lilly And Company | Composition and method for treating anxiety |
IL118727A (en) | 1995-06-29 | 2003-01-12 | Lilly Co Eli | (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid |
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
ES2191412T3 (es) | 1998-01-28 | 2003-09-01 | Taisho Pharmaceutical Co Ltd | Derivados de aminoacidos que contienen fluor. |
GB9815542D0 (en) | 1998-07-17 | 1998-09-16 | Lilly Co Eli | Bicyclohexane derivatives |
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
WO2002055485A1 (fr) | 2001-01-11 | 2002-07-18 | Eli Lilly And Company | Promedicaments d'acides amines excitateurs |
EP1423411A2 (fr) | 2001-07-09 | 2004-06-02 | Eli Lilly And Company | Promedicaments d'acides amines excitateurs |
AU2002353845A1 (en) | 2001-11-23 | 2003-06-10 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
AU2002361611A1 (en) | 2001-12-21 | 2003-07-24 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
-
2001
- 2001-12-14 HU HU0400620A patent/HUP0400620A3/hu unknown
- 2001-12-14 IL IL15636401A patent/IL156364A0/xx unknown
- 2001-12-14 US US10/250,448 patent/US7256217B2/en not_active Expired - Fee Related
- 2001-12-14 CN CNB018219667A patent/CN1267407C/zh not_active Expired - Fee Related
- 2001-12-14 NZ NZ526050A patent/NZ526050A/en unknown
- 2001-12-21 PL PL361669A patent/PL208413B1/pl unknown
- 2001-12-21 BR BR0116770-7A patent/BR0116770A/pt not_active IP Right Cessation
- 2001-12-21 DE DE60127182T patent/DE60127182T2/de not_active Expired - Lifetime
- 2001-12-21 JP JP2002556156A patent/JP4064237B2/ja not_active Expired - Fee Related
- 2001-12-21 MX MXPA03006186A patent/MXPA03006186A/es active IP Right Grant
- 2001-12-21 DZ DZ013461A patent/DZ3461A1/fr active
- 2001-12-21 CZ CZ20031916A patent/CZ303490B6/cs not_active IP Right Cessation
- 2001-12-21 CA CA2433667A patent/CA2433667C/fr not_active Expired - Fee Related
- 2001-12-21 ES ES01989859T patent/ES2282315T3/es not_active Expired - Lifetime
- 2001-12-21 SK SK826-2003A patent/SK287934B6/sk not_active IP Right Cessation
- 2001-12-21 EP EP01989859A patent/EP1368304B1/fr not_active Expired - Lifetime
- 2001-12-21 AU AU2002228737A patent/AU2002228737B2/en not_active Ceased
- 2001-12-21 AT AT01989859T patent/ATE356111T1/de not_active IP Right Cessation
- 2001-12-21 KR KR10-2003-7009216A patent/KR20030090622A/ko not_active Application Discontinuation
- 2001-12-21 WO PCT/US2001/045866 patent/WO2002055481A1/fr active IP Right Grant
-
2002
- 2002-01-10 PE PE2002000010A patent/PE20020829A1/es not_active Application Discontinuation
- 2002-01-11 SV SV2002000836A patent/SV2003000836A/es not_active Application Discontinuation
- 2002-01-11 AR ARP020100085A patent/AR036007A1/es unknown
-
2003
- 2003-07-10 NO NO20033166A patent/NO20033166L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL189355A0 (en) | Prodrugs of excitatory amino acids | |
IL173382A0 (en) | Amino acid prodrugs | |
EP1377587A4 (fr) | Inhibiteurs de proteine phosphate | |
HUP0300299A3 (en) | Composition comprising free amino acids | |
NO20026283L (no) | Inhibitorer av kobberholdige aminosydaser | |
PL372413A1 (en) | Phosphate prodrugs of fluorooxindoles | |
NO20052807D0 (no) | Fremgangsmate for fremstilling av aminosyrer | |
EP1255542A4 (fr) | Acides amines substitues comme inhibiteurs de sphingomyelinase neutre | |
AU2003215014A8 (en) | Amino acids factory | |
IL156364A0 (en) | Prodrugs of excitatory amino acids | |
AU2002353845A1 (en) | Prodrugs of excitatory amino acids | |
PL371427A1 (en) | New uses of substituted aminoalkanephosphonic acids | |
AU2002361611A1 (en) | Prodrugs of excitatory amino acids | |
EP1399467A4 (fr) | Promedicaments actives par peptide deformylase | |
GB0116047D0 (en) | Peptide motif for therapy | |
TWI315666B (en) | Prodrugs of excitatory amino acids | |
AU2002241827A1 (en) | Prodrugs of excitatory amino acids | |
AU2002345789A1 (en) | Prodrugs of excitatory amino acids | |
AU2003242924A1 (en) | Prodrugs of excitatory amino acids | |
AU2002239938A1 (en) | Synthetic excitatory amino acids | |
AU2003245571A1 (en) | Preparation of protected amino acids | |
EP1466975A4 (fr) | Proteines postsynaptiques | |
GB0025386D0 (en) | Branched amino acids | |
GB0123114D0 (en) | Protein production | |
PL346802A1 (en) | Novel amino esters of fatty acids |